Nebivolol/valsartan explained
| Type: | combo |
| Component1: | Nebivolol |
| Class1: | Beta blocker |
| Component2: | Valsartan |
| Class2: | Angiotensin II receptor blocker (ARB) |
| Tradename: | Byvalson, Vyduo |
| Dailymedid: | Nebivolol hydrochloride and valsartan |
| Routes Of Administration: | By mouth |
| Atc Prefix: | C09 |
| Atc Suffix: | DX05 |
| Legal Us: | Rx-only |
| Cas Number: | 1268819-57-3 |
| Pubchem: | 73050811 |
| Kegg: | D11388 |
Nebivolol/valsartan, sold under the brand name Byvalson among others, is a medication used to treat hypertension.[1] [2]
It is available as a generic medication.[3]
Further reading
- Ishak J, Rael M, Punzi H, Gradman A, Anderson LM, Patel M, Ali S, Ferguson W, Neutel J . 6 . Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension . Journal of Clinical Hypertension . 20 . 1 . 143–149 . January 2018 . 29105958 . 5813198 . 10.1111/jch.13132 . doi . free .
External links
Notes and References
- Web site: Byvalson (nebivolol and valsartan) tablets, for oral use Initial U.S. Approval: 2016 . DailyMed . 23 September 2022 . 24 September 2022 . https://web.archive.org/web/20220924035633/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=407644 . live .
- Lamberton NH, Copenhaver AM . Nebivolol/Valsartan (Byvalson) for Hypertension . American Family Physician . 97 . 2 . 124–125 . January 2018 . 29365224 . 24 September 2022 . live . https://web.archive.org/web/20220924035737/https://www.aafp.org/pubs/afp/issues/2018/0115/p124.html . 24 September 2022 .
- Web site: 2022 First Generic Drug Approvals . U.S. Food and Drug Administration (FDA) . 3 March 2023 . https://web.archive.org/web/20230630003602/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals . 30 June 2023 . live . 30 June 2023.
